A patient is prescribed propranolol for migraine prevention. Which assessment finding would be a priority to report to the provider?

Choice A rationale: While a decreased frequency of migraine headaches is a positive outcome, it does not directly indicate the immediate therapeutic effect of a sumatriptan (a serotonin receptor agonist). It may suggest a preventive effect over time.
Choice B rationale: Complete absence of migraine headaches is a positive outcome, but it is not always achievable. Immediate cessation of all headaches might not be realistic with every dose.
Choice C rationale: This is correct. Sumatriptan, a serotonin receptor agonist, is designed to terminate or relieve an ongoing migraine headache when administered during an attack. The patient reporting the termination of the migraine headache after drug administration suggests the desired therapeutic effect.
Choice D rationale: Increased nausea is not a desired therapeutic effect of sumatriptan. Sumatriptan is used to relieve the symptoms of migraines, including nausea, not exacerbate them.

Choice A rationale: Methylphenidate is a central nervous system stimulant, and excessive caffeine intake can exacerbate its stimulant effects. Consuming an unlimited number of cola soft drinks, which typically contain caffeine, is not advisable. The patient should be educated to moderate caffeine intake to avoid potential interactions and side effects.
Choice B rationale: Methylphenidate can interact with caffeine, so avoiding chocolate, coffee, and tea is a valid recommendation to prevent excessive stimulant effects.
Choice C rationale: Decaffeinated coffee still contains a small amount of caffeine, and patients taking methylphenidate should be aware of this to manage their overall caffeine intake.
Choice D rationale: Taking methylphenidate after breakfast is a common recommendation to minimize appetite suppression and potential weight loss associated with the medication.